Filing Flows › Starling Oncology (STLN) › Q1 2025
Starling Oncology (STLN) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 14, 2025
Starling Oncology (STLN) reported revenue of $104M for the first quarter 2025 (Q1 2025), +10% from a year earlier and +4% from the quarter before. Operating margin was -9.5%, net loss $19.6M (18.8% of revenue).
Starling Oncology, Q1 2025: revenue $104M (+10% year over year), operating margin -9.5%, net loss $19.6M, operating cash flow −$5.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $104M | +4% | +10% |
| Operating profit | −$9.9M | — | — |
| Net earnings | −$19.6M | — | — |
| Operating cash flow | −$5.0M | — | — |
What changed
Revenue was $104.4M in Q1 2025, up 10% year over year and up 4% from the previous quarter. Dispensary was the largest line at 47% of revenue. Dispensary added $9.6M year over year (up 24%), 99% of the total change. Clinical trials & other declined 19%.
Operating costs exceeded revenue by $9.9M, an operating margin of -9.5%. Total costs grew 1% against revenue growth of 10%. The quarter ended with a net loss of $19.6M, wider than the previous quarter's $13.2M loss.
Operating cash flow was −$5.0M. Non-cash charges added back $1.8M of depreciation and amortization and $1.5M of share-based compensation. Working capital and other items added $11.4M. Capital expenditures of $328K exceeded it, leaving free cash flow of −$5.3M.
Questions
What was Starling Oncology's revenue in the first quarter 2025?
Starling Oncology (STLN) reported revenue of $104M for the first quarter 2025 (Q1 2025), +10% from a year earlier and +4% from the quarter before.
Was Starling Oncology profitable in the first quarter 2025?
Operating loss was $9.9M (-9.5% of revenue) and net loss $19.6M.
Source: Starling Oncology 10-Q on SEC EDGAR.